Following Cathie Wood: Aggressively buying the 'AI+healthcare' rising star Tempus AI (TEM), selling TWST after earnings, and cashing out on AMD at higher levels

Overnight and this morning, benefiting from the continued surge in AI-related assets, the S&P 500 and Nasdaq indices hit record highs for the second consecutive day. Additionally, news of the US-Iran 'ceasefire memorandum' triggered a sharp drop in international oil prices, further boosting market sentiment. At the close, the S&P 500 Index rose 1.46% (to 7,365.12 points); the Nasdaq climbed 2.02% (to 25,838.94 points); and the Dow Jones Industrial Average gained 1.24% (to 49,910.59 points).

In the current market conditions, Cathie Wood's portfolio adjustment strategy is clear: on the buying side, she has significantly increased her position in Tempus AI, a unicorn specializing in big data for precision medicine,$Tempus AI (TEM.US)$and continued to add to her core holdings in gene-editing stocks.$Intellia Therapeutics (NTLA.US)$On the selling side, she continued to unload shares of a synthetic biology company that reported widening losses,$Twist Bioscience (TWST.US)$and extended profit-taking on chip giant$Advanced Micro Devices (AMD.US)$.

Buying focus: Making aggressive bets on the 'AI+precision medicine' ecosystem while accumulating foundational assets in genetic repair.

Buy $Tempus AI (TEM.US)$145,800 shares.Tempus AI is a cutting-edge company focused on applying AI technology to precision medicine, with a vast clinical and molecular database. The current stock price is relatively low historically, and ARK's significant position building echoes its earlier concentrated investments. $GeneDx Holdings (WGS.US)$

Add to position$Intellia Therapeutics (NTLA.US)$28,200 shares.Following the massive purchases of hundreds of thousands of shares at the end of April and early May, ARK continues to maintain its buying pace for NTLA. As a pioneer in the field of in vivo gene editing, NTLA is considered a core target for curing genetic diseases in the future. ARK's continuous increase in holdings reflects its absolute confidence in the commercial prospects of 'next-generation gene therapy' technology.

Selling direction: Reducing holdings of TWST after the earnings report due to widening losses, continuing to cash out semiconductor hardware at high levels.

On the sell side, ARK’s discipline of 'weeding out the weak and keeping the strong' and 'sector rotation' is still being implemented.

Reduce holdings $Twist Bioscience (TWST.US)$61,400 shares.Twist Bioscience recently announced its fiscal Q2 2026 results on May 4: although revenue grew 19% year-over-year to $110.7 million, the company remains unprofitable. Facing a volatile macro environment, ARK is reducing risk exposure to highly volatile innovative stocks. By taking profits in overvalued stocks, ARK is reallocating funds from unprofitable TWST to targets with stronger short-term upside potential or deeper technological moats, aiming to improve overall portfolio capital efficiency.

Reduce holdings $Advanced Micro Devices (AMD.US)$18,900.The company released a comprehensive Q1 earnings report that exceeded expectations and doubled its CPU market growth forecast for the coming years. The stock price surged by 18.61% at one point, hitting a record high. With the current share price at historical highs, ARK is systematically locking in profits from hardware positions and redirecting liquidity to AI healthcare application layers like Tempus AI (TEM), where valuations are more explosive.

Futubull [Opportunities page] Now featuring the ability to track portfolios of renowned investors! Choose from multiple celebrity holdings, follow the investment strategies of top players with one click, accurately target high-quality stocks, and invest with greater confidence!

59K Views